THAR Tharimmune, Inc.: Operating Profitability

High barriers to entry driven by antibody patents determine the market resilience of Tharimmune, Inc. (THAR). Historical operating margin levels confirm this position, where the value of 0.00 represents the most recent figure. This trend is based on the success of itch therapy for liver pathologies, while long-term growth relies on independence from macroeconomic fluctuations and the progress of clinical trials.
Analytical breakdowns for Tharimmune, Inc. (THAR)

Investors should evaluate the financial stability of Tharimmune, Inc. (THAR) through the portion of revenue remaining after covering operating expenses before taxes and interest. When analyzing the operating profit margin, it is important to note that the absence of commercial revenue and laboratory costs render this indicator negative, reflecting an increase in unit costs as antibody clinical trials expand.